title: BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.
abstract: In our continued attempts to identify novel and effective pan-Bcl-2 antagonists, we have recently reported a series of compound 2 (Apogossypol) derivatives, resulting in the chiral compound 4 (8r). We report here the synthesis and evaluation on its optically pure individual isomers. Compound 11 (BI-97C1), the most potent diastereoisomer of compound 4, inhibits the binding of BH3 peptides to Bcl-X(L), Bcl-2, Mcl-1, and Bfl-1 with IC(50) values of 0.31, 0.32, 0.20, and 0.62 microM, respectively. The compound also potently inhibits cell growth of human prostate cancer, lung cancer, and lymphoma cell lines with EC(50) values of 0.13, 0.56, and 0.049 microM, respectively, and shows little cytotoxicity against bax(-/-)bak(-/-) cells. Compound 11 displays in vivo efficacy in transgenic mice models and also demonstrated superior single-agent antitumor efficacy in a prostate cancer mouse xenograft model. Therefore, compound 11 represents a potential drug lead for the development of novel apoptosis-based therapies against cancer.
authors.affiliation: Sanford-Burnham Medical Research Institute, La Jolla, California 92037, USA.
authors.forename: Jun
authors.initials: J
authors.lastname: Wei
authors.forename: John L
authors.initials: JL
authors.lastname: Stebbins
authors.forename: Shinichi
authors.initials: S
authors.lastname: Kitada
authors.forename: Rupesh
authors.initials: R
authors.lastname: Dash
authors.forename: William
authors.initials: W
authors.lastname: Placzek
authors.forename: Michele F
authors.initials: MF
authors.lastname: Rega
authors.forename: Bainan
authors.initials: B
authors.lastname: Wu
authors.forename: Jason
authors.initials: J
authors.lastname: Cellitti
authors.forename: Dayong
authors.initials: D
authors.lastname: Zhai
authors.forename: Li
authors.initials: L
authors.lastname: Yang
authors.forename: Russell
authors.initials: R
authors.lastname: Dahl
authors.forename: Paul B
authors.initials: PB
authors.lastname: Fisher
authors.forename: John C
authors.initials: JC
authors.lastname: Reed
authors.forename: Maurizio
authors.initials: M
authors.lastname: Pellecchia
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D017209:Apoptosis; D001667:Binding, Competitive; D049109:Cell Proliferation / Q000187:drug effects; D002851:Chromatography, High Pressure Liquid; D004354:Drug Screening Assays, Antitumor; D005454:Fluorescence Polarization; D006072:Gossypol / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D051379:Mice; D008822:Mice, Transgenic; D008958:Models, Molecular; D009368:Neoplasm Transplantation; D011485:Protein Binding; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013237:Stereoisomerism; D014183:Transplantation, Heterologous
chemical_list: C550162:1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-N5-(2-phenylpropyl)-N5'-(2-phenylpropyl)-2,2'-binaphthyl-5,5'-dicarboxamide; D000970:Antineoplastic Agents; D019253:Proto-Oncogene Proteins c-bcl-2; C492806:apogossypol; D006072:Gossypol